Emergent BioSolutions (EBS) CFO logs PSU award, share disposition

Rhea-AI Filing Summary

Emergent BioSolutions EVP and CFO Richard S. Lindahl reported equity award activity tied to performance stock units and tax withholding. On February 6, 2026, he disposed of 46,155 shares of common stock at $10.92 per share and had 245,342 shares beneficially owned immediately afterward.

The filing explains that 2023–2025 performance stock units under the company’s stock incentive plan were certified at 25% of target, resulting in an actual award of 15,384 shares of common stock. In a separate transaction the same day, 5,642 shares at $10.92 per share were withheld to cover taxes on vesting, leaving Lindahl with 239,700 directly owned shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider LINDAHL RICHARD S

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Disposition	Common Stock	46,155	$10.92	$504K
Tax Withholding	Common Stock	5,642	$10.92	$62K

Holdings After Transaction: Common Stock — 245,342 shares (Direct)

Footnotes (1)

1. Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 15,384 shares of common stock, which is less than the 61,539 shares previously reported on March 02, 2023 and June 09, 2023. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LINDAHL RICHARD S

(Last) (First) (Middle)

300 PROFESSIONAL DRIVE

(Street)

GAITHERSBURG MD 20879

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		D		46,155(1)	D	$10.92	245,342	D
Common Stock	02/06/2026		F		5,642(2)	D	$10.92	239,700	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 15,384 shares of common stock, which is less than the 61,539 shares previously reported on March 02, 2023 and June 09, 2023.

2. Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

Remarks:

	/s/ Richard S. Lindahl	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did EBS CFO Richard Lindahl report on February 6, 2026?

Richard S. Lindahl reported disposing of 46,155 Emergent BioSolutions (EBS) common shares at $10.92 each and a separate withholding of 5,642 shares at $10.92 for taxes. After these transactions, he directly owned 239,700 shares of EBS common stock.

How were Emergent BioSolutions (EBS) 2023–2025 performance stock units paid out?

The 2023–2025 performance stock units for Emergent BioSolutions (EBS) were certified at 25% of target on February 6, 2026. This resulted in an actual award of 15,384 common shares, compared with 61,539 shares previously reported as the target opportunity for that PSU grant.

What do the D and F transaction codes mean in the EBS CFO’s Form 4?

In the EBS Form 4, code D reflects a disposition of 46,155 common shares at $10.92, while code F reflects 5,642 shares withheld at $10.92 to cover taxes on restricted stock unit vesting and settlement. Both transactions relate to equity compensation activity, not open-market purchases.

How many Emergent BioSolutions (EBS) shares does the CFO hold after these Form 4 transactions?

Following the reported February 6, 2026 transactions, EBS EVP and CFO Richard S. Lindahl beneficially owned 239,700 shares of Emergent BioSolutions common stock directly. This figure reflects both the disposition of 46,155 shares and the 5,642 shares withheld for associated tax obligations.

What performance period governed the EBS CFO’s performance stock units in this Form 4?

The performance stock units covered in the Form 4 vest based on cumulative revenues and adjusted EBITDA as a percentage of GAAP revenue over a three-year period. That period runs from January 1, 2023 through December 31, 2025, with final certification occurring on February 6, 2026.